New hope for kids with Crohn's: drug trial targets gut inflammation
NCT ID NCT07298421
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 19 times
Summary
This study tests a new medicine called afimkibart in 100 children aged 2 to 17 with moderate to severe Crohn's disease. The goal is to see if the drug can safely reduce gut inflammation and bring symptoms under control. Participants will receive either the drug or a placebo, and doctors will monitor their response over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.